BioLineRx (BLRX) Misses Q2 EPS by 1c

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

The Company held $52.6 million in cash, cash equivalents and short-term bank deposits as of June 30, 2017. In July 2017, the Company completed a direct placement of its securities for net proceeds of $9.5 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Goldman "broadly" raises estimates for LTL and truckload stocks
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)